DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Wegovy (semaglutide 2.4mg) is an FDA-approved once-weekly injection for adults with obesity or overweight with comorbidities.
Strong, well-studied weight loss with real trade-offs
Wegovy is among the most effective FDA-approved weight-management medications, with average weight loss near 15% of body weight in pivotal trials and a documented 20% reduction in heart attack, stroke, and cardiovascular death in adults who have established cardiovascular disease and are overweight or obese (but do not have diabetes). It is not a quick fix: it requires weekly injections (or a newer daily pill), causes gastrointestinal side effects in most users, and works only as long as you keep taking it. For the right candidate willing to commit, the evidence base is strong, but the decision should be made with a prescriber.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Wegovy is the brand name for semaglutide dosed at 2.4 mg once weekly, made by Novo Nordisk. It is the same molecule as Ozempic (the type 2 diabetes brand) and Rybelsus (the oral diabetes pill), but Wegovy is the version specifically approved and titrated for weight management at a higher target dose.
The FDA first approved Wegovy in June 2021 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol (FDA). In late 2022 it was expanded to adolescents aged 12 and older with obesity (FDA).
In March 2024 the FDA approved a major new indication: reducing the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, and non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight (FDA). This made Wegovy the first weight-management medication shown to deliver a cardiovascular benefit, a distinction that matters because it reframes the drug as more than cosmetic.
Two things it is *not*: Wegovy is not approved purely for type 2 diabetes glucose control (that is Ozempic's lane), and it is not approved for people who simply want to lose a few pounds without meeting the BMI thresholds.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone your gut naturally releases after eating; it signals the pancreas to release insulin, suppresses the counter-hormone glucagon, and acts on the brain's appetite centers. Semaglutide mimics this hormone but is engineered to resist rapid breakdown, giving it a half-life of about a week — which is why it is dosed only once every seven days (NIH).
The weight-loss effect comes mainly from the brain, not the pancreas. Semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and increase satiety, so people feel full sooner and stay full longer. It also slows gastric emptying, meaning food leaves the stomach more slowly. The net result is a meaningful, mostly involuntary reduction in calorie intake. This mechanism also explains the most common side effects — nausea, fullness, and constipation are downstream of slowed digestion and suppressed appetite.
This is where the evidence is genuinely strong. In the pivotal STEP 1 trial (1,961 adults with overweight/obesity but without diabetes), participants on semaglutide 2.4 mg plus lifestyle support lost an estimated mean of 14.9% of body weight at 68 weeks, versus 2.4% on placebo (NEJM 2021; PMID 33567185). About 86% reached at least 5% weight loss, and roughly one-third lost 20% or more — results that approach what some bariatric procedures achieve.
For an average 230-pound (104 kg) adult, 15% translates to about 34 pounds. Real-world results are typically somewhat lower than trial averages, partly because clinical-trial participants receive structured lifestyle counseling and partly because some people stop early due to side effects, cost, or supply.
The cardiovascular data give the drug a second, independent reason to take it. In the SELECT trial — 17,604 adults with established cardiovascular disease and overweight/obesity but no diabetes — semaglutide reduced the risk of major adverse cardiovascular events by 20% versus placebo over an average of about three years (NEJM 2023; PMID 37952131). Importantly, this benefit appeared early and was only partly explained by weight loss, suggesting direct cardiovascular and anti-inflammatory effects.
Obesity behaves like a chronic disease, and the trials show the effect is maintenance-dependent. In the STEP 4 withdrawal trial, people who switched to placebo after reaching the full dose regained weight (a 6.9% increase over the following 48 weeks), while those who continued semaglutide lost an additional ~7.9% (JAMA 2021; PMID 33755728). A one-year follow-up of STEP 1 found participants regained roughly two-thirds of their lost weight after stopping (Diabetes Obes Metab 2022). Practically, Wegovy is not a short course — it is an ongoing treatment, and budgeting and expectations should reflect that.
Wegovy is a once-weekly subcutaneous injection (abdomen, thigh, or upper arm) given on the same day each week, with or without food. Dosing is deliberately slow to limit nausea — the standard escalation runs over roughly 16 weeks (FDA label):
If a particular step causes intolerable side effects, the prescriber can pause escalation or hold at a lower dose before advancing. Skipping the titration to "get there faster" reliably backfires with severe GI symptoms. A higher 7.2 mg formulation has also become available for some patients seeking additional effect; this should only be used under clinician guidance.
Common side effects are predominantly gastrointestinal and usually peak during dose escalation, then ease: nausea, diarrhea, vomiting, constipation, abdominal pain, and fatigue. They affect a large share of users to some degree, and are the main reason people discontinue. Eating smaller, lower-fat meals and stopping when full helps.
Serious but less common risks noted on the FDA label include:
Boxed warning and contraindications: Wegovy carries an FDA boxed warning for thyroid C-cell tumors, based on rodent studies showing medullary thyroid carcinoma (the human relevance is unconfirmed). It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in those with a known serious hypersensitivity to semaglutide (FDA).
Avoid in pregnancy. Semaglutide should be stopped at least two months before a planned pregnancy because of its long half-life and animal data suggesting fetal harm (FDA).
Interactions are mostly mechanical rather than chemical: delayed gastric emptying can alter the absorption of oral medications, and insulin/sulfonylurea doses often need lowering to prevent hypoglycemia.
A strong fit if you: meet the BMI criteria (≥30, or ≥27 with a weight-related condition); have struggled with sustained weight loss through diet and exercise alone; have established cardiovascular disease (where the SELECT benefit applies); and are prepared to treat obesity as a long-term, ongoing condition rather than a quick fix.
Reconsider or avoid if you: have a personal or family history of MTC or MEN 2; have had pancreatitis; are pregnant, breastfeeding, or planning pregnancy soon; have severe gastroparesis or a history of significant GI disease; or cannot realistically sustain the cost long-term, since stopping tends to reverse the gains. People seeking modest cosmetic weight loss without meeting clinical criteria are not appropriate candidates, and the drug should always be paired with nutrition and activity changes — the trials all included lifestyle support.
Wegovy's list price is about $1,349 per month, but very few people pay that. With commercial insurance coverage, eligible patients may pay far less through Novo Nordisk savings programs. The bigger story for the uninsured or unreimbursed is the manufacturer's cash-pay option through NovoCare Pharmacy: as of late 2025 Novo Nordisk lowered the standard self-pay price to about $349/month for the maintenance strengths (down from $499), with a reduced introductory price for the first one to two months of the lower starter doses and a slightly higher self-pay price for the new 7.2 mg strength. Always confirm current pricing directly with NovoCare or your pharmacy, as these programs change frequently.
The two practical hurdles are coverage and supply. Many commercial plans require prior authorization or exclude obesity drugs entirely; Medicare historically did not cover medications used purely for weight loss, though the cardiovascular indication has opened some coverage pathways for patients with qualifying heart disease. After years of intermittent shortages, supply has largely stabilized.
A word of caution on compounded semaglutide: telehealth platforms still advertise compounded versions at roughly $99–$269/month, though the gap versus brand self-pay has narrowed now that NovoCare's cash price has dropped. More importantly, compounded products are not FDA-approved, are not the identical Novo Nordisk product, and now that semaglutide is off the FDA shortage list (since early 2025), large-scale compounding is far more restricted and generally limited to documented clinical need. Quality, dosing accuracy, and the actual active ingredient (some have used semaglutide salts of uncertain equivalence) vary. Treat cheap compounded GLP-1s with real skepticism.
Wegovy vs. Zepbound (tirzepatide): This is the central comparison in 2026, and the head-to-head data favor Zepbound for raw weight loss. In SURMOUNT-5, the first direct trial, tirzepatide produced a mean 20.2% weight loss versus 13.7% for semaglutide at 72 weeks (NEJM 2025; PMID 40353578). Zepbound is a dual GIP/GLP-1 agonist, which appears to drive the larger effect, and it also had fewer GI-related discontinuations in that trial. Wegovy's counterweight is its proven cardiovascular outcomes data (SELECT), which Zepbound does not yet match for that specific indication. If maximum weight loss is the goal, the evidence leans Zepbound; if you have established heart disease, Wegovy has the clearer outcomes case.
Wegovy vs. Saxenda (liraglutide): Older daily GLP-1. In the STEP 8 head-to-head, semaglutide produced 15.8% weight loss versus 6.4% for liraglutide at 68 weeks (JAMA 2022; PMID 35017634) — Wegovy is clearly more effective and requires only weekly rather than daily injections.
Wegovy vs. Ozempic: Same molecule, different approved use and max dose. Ozempic is approved for diabetes and tops out at 2 mg; Wegovy is titrated to 2.4 mg for weight management. Using Ozempic "off-label" for weight loss is common but means no obesity-specific approval and inconsistent coverage.
Wegovy vs. the oral pill: An oral version of Wegovy (semaglutide 25 mg, once daily) was FDA-approved for chronic weight management — the first oral GLP-1 cleared for weight loss — based on the OASIS program, which showed roughly 16.6% mean weight loss at 64 weeks with full adherence. The pill offers needle-free convenience, though its average effect in trials was somewhat below the ~15-17% seen with the injection and it must be taken daily on an empty stomach with strict timing rules. For maximum weight loss the injectable formulation still has the deeper outcomes record (including the SELECT cardiovascular data), but the oral option is now a legitimate alternative for people who prefer to avoid injections.
Wegovy is one of the most effective non-surgical obesity treatments ever brought to market, with about 15% average weight loss in trials, a genuine and independently valuable cardiovascular benefit for people with heart disease, and a strong, transparent evidence base behind it. Its real limitations are honest ones: it is a chronic, indefinite therapy (weight returns when you stop), it commonly causes GI side effects during titration, it carries specific contraindications, and cost plus coverage remain the biggest practical barriers for most people. If you meet the clinical criteria and can sustain it, Wegovy is a well-supported choice — though anyone prioritizing the greatest possible weight loss should weigh the head-to-head data favoring tirzepatide (Zepbound), and everyone should treat it as one part of a long-term, medically supervised plan rather than a standalone solution. Decisions about starting, switching, or stopping should be made with a licensed clinician who knows your full history.
*This article is for educational purposes and is not medical advice. HealthVetted is independent, accepts no payment for placement, and sells none of the products it reviews.*
Wegovy's active ingredient, semaglutide, mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). By activating GLP-1 receptors in the brain's appetite centers, it reduces hunger, increases feelings of fullness, and slows how quickly the stomach empties. The result is that most people naturally eat less and feel satisfied on smaller portions. It also improves how the body handles blood sugar. Because it does not "burn fat" directly, it works largely by lowering calorie intake, which is why diet and physical activity remain part of treatment.
Active ingredient: Semaglutide
In the pivotal STEP 1 trial (NEJM, 2021; 1,961 adults with overweight or obesity but without diabetes), weekly semaglutide 2.4 mg produced an average weight loss of about 14.9% of body weight at 68 weeks versus roughly 2.4% with placebo, and about 86% of treated participants lost at least 5% of their body weight. The 2-year STEP 5 trial (Nature Medicine, 2022) showed sustained results with continued use: about 15.2% mean weight loss versus 2.6% with placebo at 104 weeks. In the large SELECT cardiovascular outcomes trial (NEJM, 2023; 17,604 adults with established cardiovascular disease, overweight or obese, without diabetes), semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% versus placebo (hazard ratio 0.80). The newer oral Wegovy 25 mg pill produced about 16.6% mean weight loss among participants who adhered to treatment in the OASIS 4 trial. Individual results vary.
A realistic timeline of what Wegovy users typically experience. Individual results vary; this is educational, not medical advice.
You begin at 0.25 mg injected once weekly - a deliberately low "starter" dose meant to let your body adjust, not to drive weight loss. Mild GI side effects (nausea, fullness, constipation) are most common in this window; many people also notice early appetite changes or quieter "food noise." Significant scale movement is not expected yet.
The dose steps up roughly every 4 weeks (0.5, then 1.0, then 1.7 mg) so your body acclimates gradually. Nausea or queasiness often flares briefly after each increase and usually eases within days to a couple of weeks. Measurable weight loss typically begins in this phase, with appetite suppression becoming more noticeable as the dose rises.
Most reach the full 2.4 mg maintenance dose around week 16-20 (some stay at 1.7 mg if it works well and is tolerated). Weight loss tends to accelerate at the higher doses. Side effects generally settle as you stabilize, though individual tolerance varies.
In the STEP 1 trial, many participants had lost roughly 10-15% of starting body weight by this point, though results vary widely - some lose more, some less, and a minority respond minimally. Loss is gradual and depends on adherence plus diet and activity.
Average total weight loss in STEP 1 was about 14.9% at 68 weeks (versus ~2.4% on placebo). Weight loss usually slows and plateaus somewhere in this period as your body reaches a new set point. This is expected, not a sign the medication has stopped working.
Wegovy is intended for long-term, chronic use under medical supervision; it manages weight rather than curing obesity. Studies show weight tends to be regained after stopping, so maintaining results generally means continuing treatment alongside lifestyle changes. Discuss duration, monitoring, and any persistent side effects with your prescriber.
The most common side effects (each occurring in 5% or more of users in trials) are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, bloating, and indigestion, along with headache, fatigue, and dizziness. These are usually mild to moderate, tend to be worst when starting or increasing the dose, and often ease over a few weeks. Serious but less common risks include pancreatitis, gallbladder problems (including gallstones), acute kidney injury from dehydration caused by vomiting or diarrhea, low blood sugar (mainly in people also taking diabetes medications such as insulin or sulfonylureas), and worsening of diabetic eye disease. Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek medical care promptly for severe, persistent abdominal pain (a possible sign of pancreatitis). This is not a complete list; review the full label and discuss risks with your prescriber.
Sourced from FDA labeling and clinical references; not exhaustive and not a substitute for your prescriber or pharmacist. Always disclose every medication and supplement you take.
Starts at $1349/mo from Novo Nordisk.
As of 2026, Wegovy's list price is roughly $1,350 per month before insurance or discounts. Through Novo Nordisk's NovoCare self-pay program, eligible cash-paying patients without insurance can get the injection for about $349 per month for standard doses, with a limited-time promotional price near $199 per month for the lowest starter doses (0.25 mg and 0.5 mg) through mid-2026; the oral pill has its own self-pay pricing, generally lower. This self-pay price was lowered over time (it was about $499 per month in early 2025). With commercial (non-government) insurance that covers Wegovy, the manufacturer savings card can bring copays as low as $0 for eligible patients, but many plans, and most Medicare and Medicaid plans, still do not cover Wegovy for weight loss. Coverage and out-of-pocket costs vary widely and change frequently, so verify current pricing for your specific dose and plan directly with NovoCare and your pharmacy.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
Wegovy delivers some of the strongest non-surgical weight-loss results available, backed by large randomized trials and a documented cardiovascular benefit in one high-risk population. The trade-offs are real: frequent GI side effects, ongoing cost if uninsured, and weight regain when you stop. For people with obesity, or overweight plus a weight-related condition, it is one of the most effective options available in 2026 if you can sustain it. This is a prescription medication; only a clinician can decide whether it is right for you.
In the pivotal STEP 1 trial, adults with overweight or obesity but without diabetes lost an average of about 15% of their body weight over 68 weeks on weekly semaglutide 2.4 mg, compared with about 2% on placebo. About 86% of treated participants lost at least 5% of their weight. Individual results vary, and weight loss is greatest when the medication is combined with a reduced-calorie diet and increased activity.
Both Wegovy and Ozempic contain the same active drug, semaglutide, but they are approved for different uses. Wegovy is FDA-approved for chronic weight management at a higher maximum dose (2.4 mg), while Ozempic is approved for type 2 diabetes (maximum 2 mg). They are not interchangeable and use different pens and dosing schedules. Your prescriber decides which, if either, is appropriate.
Wegovy's list price is roughly $1,350 per month. As of 2026, Novo Nordisk's NovoCare self-pay program offers the injection to eligible cash-paying patients for about $349 per month for standard doses, with a limited-time promotional price near $199 per month for the lowest starter doses through mid-2026. With commercial insurance that covers Wegovy, the manufacturer savings card can lower copays for eligible patients, but many plans do not cover it for weight loss. Prices change often, so confirm current pricing with NovoCare and your pharmacy.
Most people regain a significant portion of their lost weight after stopping, because appetite and hunger signals return toward baseline. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within roughly a year of stopping. For this reason, Wegovy is generally considered a long-term treatment rather than a short course. Talk to your prescriber before changing or stopping the medication.
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. They are usually mild to moderate, tend to be worst when the dose is being increased, and often improve within a few weeks. Less common but serious risks include pancreatitis and gallbladder problems. Seek medical care for severe, persistent abdominal pain, and review the full label with your prescriber.
Wegovy should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or by those with a known serious allergy to semaglutide. It should not be used during pregnancy and, because of the drug's long half-life, the label advises stopping at least 2 months before a planned pregnancy. People with a history of pancreatitis, gallbladder disease, or kidney problems should use it cautiously and only under medical supervision.
Yes. The FDA approved an oral Wegovy 25 mg tablet on December 22, 2025, with a US launch in early 2026. In the OASIS 4 trial it produced about 16.6% mean weight loss among participants who adhered to treatment, broadly comparable to the injection, but it must be taken daily on an empty stomach with strict timing rules (no other food, drink, or medication for 30 minutes after). Your prescriber can advise which form suits you.
Many people notice reduced appetite within the first few weeks, but the dose is increased gradually over about 16 weeks, and meaningful weight loss typically builds over several months. In the pivotal trials, the largest results were measured at 68 weeks and beyond, so it is best viewed as a long-term treatment.
Yes, in a specific group. The SELECT trial of 17,604 adults who had established cardiovascular disease and were overweight or obese (without diabetes) found that Wegovy reduced major cardiovascular events (cardiovascular death, non-fatal heart attack, and non-fatal stroke) by 20% versus placebo. This led to an FDA-approved cardiovascular indication for adults with established heart disease who are overweight or obese. The benefit has not been demonstrated in lower-risk groups.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Legitimate ways to lower your cost. We don’t sell Wegovy — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
The maker of Wegovy runs a commercial-insurance savings program that can lower your copay. See the official Wegovy savings page → Eligibility rules apply and these programs typically exclude government insurance (Medicare/Medicaid).
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
Same-category options, scored on the same six-axis rubric. Higher is better.